A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
about
The challenges and the promise of molecular targeted therapy in malignant gliomas.How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastomaLonafarnib for cancer and progeria.Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions.NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.
P2860
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A phase I trial of the farnesy ...... atients with malignant glioma.
@en
A phase I trial of the farnesy ...... atients with malignant glioma.
@nl
type
label
A phase I trial of the farnesy ...... atients with malignant glioma.
@en
A phase I trial of the farnesy ...... atients with malignant glioma.
@nl
prefLabel
A phase I trial of the farnesy ...... atients with malignant glioma.
@en
A phase I trial of the farnesy ...... atients with malignant glioma.
@nl
P2093
P2860
P50
P1476
A phase I trial of the farnesy ...... atients with malignant glioma.
@en
P2093
April D Coan
James E Herndon
James J Vredenburgh
Katherine B Peters
Stevie Threatt
P2860
P2888
P304
P356
10.1007/S11060-011-0627-0
P577
2011-07-07T00:00:00Z
P6179
1031938716